| Gene symbol | PCSK9 | Synonyms | FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p32.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | proprotein convertase subtilisin/kexin type 9 | ||||
| GTO ID | GTC1995 |
| Trial ID | NCT03705234 |
| Disease | Arteriosclerotic Cardiovascular Disease |
| Altered gene | PCSK9 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-PCSSC|Inclisiran|KJX839|Leqvio |
| Location approved | EU, UK, Australia, Canada, Israel, US, Saudi Arabia, Japan, China |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease |
| Year | 2018 |
| Country | United States|United Kingdom |
| Company sponsor | University of Oxford |
| Other ID(s) | CTSU_MDCO_PCS-17-01 |
| Vector information | |||
|
|||
| Cohort1: Inclisiran | |||||||||||
|
|||||||||||
| Cohort2: Placebo | |||||||||||
|
|||||||||||